GlassScriptPhysician profile
Hemant A Patani
NPI 1043216252
$6,553.15
in general payments reported to CMS, 2019-2025
47 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $844 · 2021: $836 · 2022: $909 · 2023: $1,195 · 2024: $1,164 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.12 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,033.05 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $782.64 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $708.77 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $550.40 | 2021-2024 | |
| Pfizer INC. | $485.02 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $274.61 | 2019-2024 | |
| Lilly USA, LLC | $268.23 | 2020-2024 | Mounjaro |
| Amarin Pharma, INC. | $239.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $234.46 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $166.11 | 2022-2025 | Veozah, Myrbetriq |
| Medtronic, INC. | $164.02 | 2023 | Endurant Iis |
| Inari Medical, INC. | $157.03 | 2022 | |
| Abbott Laboratories | $150.93 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $104.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.33 | 2019-2023 | Jardiance, Tradjenta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Patani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.